^
    20h
    Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 discriminates AGS and MKN45 cells of human gastric cancer. (PubMed, Gastroenterol Hepatol Bed Bench)
    The significantly differentially expressed genes (DEGs) from the Gene Expression Omnibus (GEO) database, which discriminate AGS and MKN45 cells in the presence of DMSO and verteporfin (a chemotherapy reagent), are determined...MKN45 was highlighted as more invasive cancer cell relative to AGS cells. PLOD2 was pointed out as a suitable target in the chemotherapy of gastric cancer.
    Journal
    |
    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    |
    Visudyne (verteporfin)
    23h
    CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation. (PubMed, Breast Cancer Res)
    This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset) • YAP1 (Yes associated protein 1) • LATS1 (Large Tumor Suppressor Kinase 1)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Visudyne (verteporfin)
    4d
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Completed, Roswell Park Cancer Institute | Terminated --> Completed
    Trial completion
    |
    Photofrin (porfimer sodium)
    5d
    SCARFREE-001: Verteporfin for Scar Prevention (2025-525083-14-00)
    P1/2, N=12, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    Visudyne (verteporfin)
    7d
    The clinical ionizable lipid SM-102 enhances photochemical immunogenic cell death by verteporfin-conjugated liposomes and improves survival in vivo. (PubMed, Photochem Photobiol Sci)
    In an immune-cold syngeneic mouse PDAC model, 690 nm light activation of SM-102-containing liposomes slowed tumor growth by up to 56% and extended survival by 40%. Together, these findings suggest that integrating SM-102 into light-activated liposomes is a simple and robust strategy to enhance photochemical ICD and may improve therapeutic outcomes in immunotherapy-based combinations that utilize liposomal drug delivery systems.
    Preclinical • Journal
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    |
    Visudyne (verteporfin)
    14d
    PHOTAC: Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068/Cl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Università degli Studi di Brescia | Trial completion date: Dec 2025 --> Apr 2027 | Initiation date: Jul 2025 --> Aug 2026 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    14d
    A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov)
    P1/2, N=32, Completed, Kiora Pharmaceuticals, Inc. | Recruiting --> Completed | N=48 --> 32 | Trial completion date: Jul 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date
    17d
    Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (clinicaltrials.gov)
    P1/2, N=66, Recruiting, SpectraCure AB | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Visudyne (verteporfin)
    21d
    Photopheresis in Early-stage Mycosis Fungoides (clinicaltrials.gov)
    P2, N=74, Recruiting, Columbia University | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    27d
    Psoralen attenuates skeletal muscle atrophy in mice with heart failure after myocardial infarction by regulating NLRP3/Caspase-1/GSDMD pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
    Male mice were randomly assigned to control, CHF, high-dose PSO, low-dose PSO, and empagliflozin(empa) groups. Compared with the 40 μmol·L~(-1) PSO group, nigericin treatment reversed these effects. In conclusion, PSO effectively attenuates skeletal muscle atrophy in CHF mice, potentially through suppression of skeletal muscle cell pyroptosis via downregulation of the NLRP3/Caspase-1/GSDMD pathway.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • GSDMD (Gasdermin D)
    1m
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    1m
    Targeted Photodynamic Activity of a Hyaluronic Acid-Protoporphyrin IX Complex via Receptor-Mediated Endocytosis. (PubMed, Chem Asian J)
    Further, the uptake of HA-1 in A549 cells was suppressed following the addition of free HA, indicating that its internalization occurred through CD44-receptor-mediated endocytosis. Moreover, the HA-1 complex exhibited better photodynamic activity against CD44-overexpressing cancer cells than both poly-L-lysine-1 complex and Photofrin, underscoring its potential as a targeted photosensitizer for photodynamic therapy.
    Journal
    |
    CD44 (CD44 Molecule)
    |
    Photofrin (porfimer sodium)